Nucleoside analog inhibitors of reverse transcriptase

• US 7,550,442 B2
• Filed: 05/19/2004
• Issued: 06/23/2009
• Est. Priority Date: 05/20/2003
• Status: Expired due to Fees

• Current Assignee: Board of Trustees of The University of Illinois
• Original Assignee: Board of Trustees of The University of Illinois
• Inventors: Liu, Xianjun, Huang, Raven H.
• Primary Examiner(s): Jiang; Shaojia Anna
• Assistant Examiner(s): Olson; Eric S
• Application Number:
  US10/848,947
• Publication Number:
  US 20040235869A1
• Time in Patent Office: 1,861 Days
• Field of Search: 514/263.28
• US Class Current: 514/45
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: C07D 405/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 473/00 Heterocyclic compounds containing purine ring systems
• CPC Class Codes: C07D 473/18 one oxygen and one nitrogen atom, e.g. guanine
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine

Abstract

Compounds of formula (XXIII), or pharmaceutically acceptable salts or esters thereof, are inhibitors of reverse transcriptase:

• R₄ is a nucleoside with Q substituting a 3′ hydroxyl group, and Q is a moiety of formulas (XXIV)-(XXXII):

Claims

1. A compound of formula (II) or (XIII-XXII) or pharmaceutically acceptable salts and esters thereof:

3. The compound of claim 1, wherein the compound is in unit dosage form.

4. A method of treating a subject infected with a retrovirus, comprising administering to the subject the compound of claim 1.

5. The method of claim 4, wherein the retrovirus is a human immunodeficiency virus.

6. The method of claim 5, wherein the subject has acquired immune deficiency syndrome.

2. A D-nucleoside selected from the group consisting of compounds of formulas (V)-(XI):

7. The compound of claim 2, wherein the compound is in unit dosage form.